Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.77 |
| ▸ | TNF | P01375 | 4/20 | 0.77 |
| ▸ | PDE4A | P27815 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.77 |
| ▸ | ACHE | P22303 | 2/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.77 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.77 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25668861 | 0.91 | ADORA2B (0.76) | ADORA2BTNFPDE4ALMNACYP1A2 | |
| SCHEMBL9123779 | 0.91 | ADORA2B (0.79) | ADORA2BTNFPDE4ALMNACYP1A2 | |
| SCHEMBL22471325 | 0.91 | TNF (0.71) | ADORA2BTNFPDE4ALMNACYP1A2 | |
| SCHEMBL9123835 | 0.90 | ADORA2B (0.74) | ADORA2BTNFPDE4ALMNACYP1A2 | |
| SCHEMBL9122988 | 0.90 | ADORA2B (0.74) | ADORA2BTNFPDE4ALMNACYP1A2 | |
| SCHEMBL9123285 | 0.90 | ADORA2B (0.74) | ADORA2BTNFPDE4ALMNACYP1A2 | |
| SCHEMBL8686059 | 0.90 | ADORA2B (0.74) | ADORA2BTNFPDE4ALMNACYP1A2 | |
| SCHEMBL10522346 | 0.89 | ADORA2B (0.76) | ADORA2BTNFPDE4ALMNACYP1A2 | |
| SCHEMBL8002916 | 0.89 | ADORA2B (0.76) | ADORA2BTNFPDE4ALMNACYP1A2 | |
| SCHEMBL19227023 | 0.88 | PDE4A (0.68) | ADORA2BTNFPDE4ALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| US-9333187-B1 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-10 | — | — | US | disclosed |
| US-20160122283-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-9187427-B2 | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2015-11-17 | — | — | US | disclosed |
| US-20150291590-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES | CELLIX BIO PRIVATE LTD (IN) | 2015-10-15 | — | — | US | disclosed |
| US-9102649-B1 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-20150148352-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS | CELLIX BIO PRIVATE LTD (IN) | 2015-05-28 | — | — | US | disclosed |
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | KANDULA MAHESH (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291590-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES | KYNU, TKT, SLC5A1 | ADORA2B 1616/4885TNF 1258/4885PDE4A 881/4885 |
| US-20160122283-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | SLC5A1, SLC5A2, SLC2A1 | ADORA2B 2558/4885TNF 2032/4885PDE4A 3055/4885 |
| US-20150148352-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS | KCNH1, TNNT2, TNNC1 | ADORA2B 379/4885TNF 575/4885PDE4A 415/4885 |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | ADORA2B 1774/4885TNF 12/4885PDE4A 1716/4885 |
| US-20150141384-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | HTT, SNCA, PARK7 | ADORA2B 1884/4885TNF 1439/4885PDE4A 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.